FANCA and head and neck squamous cell carcinoma: Overall, our CRISPR/Cas9 strategy to obtain FANCA-mutant clones from non-FA HNSCC cell lines gave adequate FA-HNSCC disease models as mutant clones, which (i) are hypersensitive to ICL-agents MMC and cisplatin, (ii) cannot monoubiquitinate FANCD2 and form nuclear foci upon MMC treatment, and (iii) display increased chromosome fragility and G2 arrest when treated with DEB.